P2‐17: Nintedanib inhibits epithelial‐mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF‐Β/Smad pathway

major source of IL-1β in MPM.Both high mobility group box 1 derived from MPM cells and asbestos-activated inflammasome in TAMs contributed the production of IL-1β, which resulted in enhancing malignant potential of MPM.Furthermore, IHC analysis demonstrated that overexpression of IL-1R tend to correlate with poor outcome in patients with MPM.